Oncotelic Therapeutics (OTCQB: OTLC), reports that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company’s intravenous Deciparticle(TM) formulation of everolimus. The biomarker framework, to be presented at the 2025 San Antonio Breast Cancer Symposium, is based on analysis of more than 9,000 tumor samples across 20 cancer types and represents the first prospective selection strategy for IV everolimus. Data show that mTORC2-dominant tumors — including HR+/HER2- breast, lung adenocarcinoma, gastric, renal, ovarian, AML and T-cell malignancies — exhibit heightened mTOR dependency and predicted sensitivity to Sapu003, which overcomes limitations of oral everolimus through higher tissue penetration, reduced GI accumulation and preserved metabolic specificity.
NOTE TO INVESTORS: The latest news and updates relating to OTLC are available in the company’s newsroom at https://nnw.fm/OTLC
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer